Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.80 |
| ▸ | P2RY1 | P47900 | 6/20 | 0.73 |
| ▸ | ENPP1 | P22413 | 3/20 | 0.73 |
| ▸ | P2RX1 | P51575 | 3/20 | 0.70 |
| ▸ | P2RX3 | P56373 | 3/20 | 0.70 |
| ▸ | P2RX2 | Q9UBL9 | 2/20 | 0.70 |
| ▸ | P2RY2 | P41231 | 2/20 | 0.67 |
| ▸ | P2RX4 | Q99571 | 2/20 | 0.67 |
| ▸ | SRC | P12931 | 1/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.67 |
| ▸ | DTYMK | P23919 | 2/20 | 0.66 |
| ▸ | RNASEL | Q05823 | 1/20 | 0.65 |
| ▸ | MACROD2 | A1Z1Q3 | 1/20 | 0.63 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.63 |
| ▸ | MACROD1 | Q9BQ69 | 1/20 | 0.63 |
| ▸ | TRPM2 | O94759 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5044161 | 1.00 | POLB (0.80) | POLBP2RY1ENPP1P2RX1P2RX3 | |
| SCHEMBL29350133 | 1.00 | POLB (0.80) | POLBP2RY1ENPP1P2RX1P2RX3 | |
| SCHEMBL3030614 | 1.00 | POLB (0.80) | POLBP2RY1ENPP1P2RX1P2RX3 | |
| SCHEMBL29702495 | 1.00 | POLB (0.80) | POLBP2RY1ENPP1P2RX1P2RX3 | |
| SCHEMBL14471000 | 1.00 | POLB (0.80) | POLBP2RY1ENPP1P2RX1P2RX3 | |
| SCHEMBL18785117 | 1.00 | POLB (0.80) | POLBP2RY1ENPP1P2RX1P2RX3 | |
| SCHEMBL78250 | 1.00 | POLB (0.80) | POLBP2RY1ENPP1P2RX1P2RX3 | |
| SCHEMBL889289 | 1.00 | POLB (0.80) | POLBP2RY1ENPP1P2RX1P2RX3 | |
| SCHEMBL31211719 | 0.99 | POLB (0.81) | POLBP2RY1ENPP1P2RX1P2RX3 | |
| SCHEMBL2508784 | 0.99 | POLB (0.81) | POLBP2RY1ENPP1P2RX1P2RX3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 418 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240076803-A1 | Method for Library Preparation in Next Generation Sequencing by Enzymatic DNA Fragmentation | Miltenyi Biotec B.V. & Co. KG (DE) | 2024-03-07 | — | — | US | claimed |
| EP-4036248-A1 | METHOD FOR LIBRARY PREPARATION IN NEXT GENERATION SEQUENCING BY ENZYMATIC DNA FRAGMENTATION | Miltenyi Biotec B.V. & Co. KG (DE) | 2022-08-03 | — | — | EP | claimed |
| US-10829812-B1 | Amplification of oligonucleotides containing non-standard nucleotides | NATIONAL SCIENCE FOUNDATION | 2020-11-10 | — | — | US | claimed |
| US-20170208853-A1 | NUTRIENT DELIVERY SYSTEM WITH HYDROLYZED PROTEINS | ABBOTT LABORATORIES (US) | 2017-07-27 | — | — | US | claimed |
| US-7794936-B1 | Using thymidine analogs to improve replication in an expanded genetic alphabet | BENNER STEVEN ALBERT | 2010-09-14 | — | — | US | claimed |
| US-20090233280-A1 | METHOD OF ACQUIRING INFORMATION REGARDING BASE SEQUENCE AND INFORMATION READING DEVICE FOR THE SAME | CANON KABUSHIKI KAISHA (JP) | 2009-09-17 | — | — | US | claimed |
| US-20090181432-A1 | PROCESS FOR SELF-ASSEMBLY OF STRUCTURES IN A LIQUID | ZAINIEV GAFUR | 2009-07-16 | — | — | US | claimed |
| US-7323452-B2 | Method for the accelerated in vivo removal of ethanol | WARDAN, L.L.C. (US) | 2008-01-29 | — | — | US | claimed |
| US-20060263779-A1 | Method for the detection of cytosine methylation patterns with high sensitivity | EPIGENOMICS AG (DE) | 2006-11-23 | — | — | US | claimed |
| EP-1590484-A2 | METHOD FOR THE DETECTION OF CYTOSINE METHYLATION PATTERNS WITH HIGH SENSITIVITY | Epigenomics AG (DE) | 2005-11-02 | — | — | EP | claimed |
| WO-2004019885-A2 | FAST DISSOLVING FILM DELIVERY OF NUCLEOTIDES THAT INHIBIT THE UNPLEASANT TASTE OF BITTER TASTING MEDICATIONS | LINGUAGEN CORP. (US) | 2004-03-11 | — | — | WO | claimed |
| EP-1025115-B1 | NOVEL NUCLEOSIDE OR NUCLEOTIDE FLUORESCENT CONJUGATES, PREPARATION METHOD AND USES | CIS BIO INT (FR) | 2003-06-04 | — | — | EP | claimed |
| US-20020015741-A1 | Method and composition for the accelerated in vivo removal of ethanol | CHEMDAN, LLC | 2002-02-07 | — | — | US | claimed |
| US-6340747-B1 | COMPLEXED TO RARE EARTH METAL CRYPTATE LABEL; DETECTION AND ISOLATION OF NUCLEIC ACIDS | CIS BIO INTERNATIONAL (FR) | 2002-01-22 | — | — | US | claimed |
| JP-2001518281-A | — | — | 2001-10-16 | — | — | JP | claimed |
| US-6103487-A | DETECTING MODULATORS THAT SUPPRESS THE ACTIVITY OF A TRANSFERASES; ANTICARCINOGENIC AGENTS | MERCK & CO., INC. (US) | 2000-08-15 | — | — | US | claimed |
| EP-1019530-A1 | A METHOD OF TREATING CANCER | Merck & Co., Inc. (US) | 2000-07-19 | — | — | EP | claimed |
| EP-1009854-A1 | A METHOD OF TREATING CANCER | Merck & Co., Inc. (US) | 2000-06-21 | — | — | EP | claimed |
| WO-1999010524-A1 | A METHOD OF TREATING CANCER | MERCK & CO., INC. (US) | 1999-03-04 | — | — | WO | claimed |
| WO-1999010523-A1 | A METHOD OF TREATING CANCER | MERCK & CO., INC. (US) | 1999-03-04 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020015741-A1 | Method and composition for the accelerated in vivo removal of ethanol | ADH1A, ADH1C, ADH5 | POLB 127/4885P2RY1 2189/4885ENPP1 174/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.